ZUBSOLV provides an opportunity for change for your opioid dependent patients.

Recovery is “a process of growth and a process of change in attitudes, thinking, and behavior.” – J Sub Abuse Treat, 2007

Study006/ISTART: A randomized, noninferiority study to assess treatment efficacy of ZUBSOLV® vs. Suboxone® film and to explore switching between treatments.¹

Key Findings: In the largest combination buprenorphine/naloxone opioid dependence trial (N=758) ever conducted in the United States, ZUBSOLV has proven to provide a comparable clinical effect to Suboxone film with the added benefit of patient-preferred attributes.²

INDICATION
ZUBSOLV® (buprenorphine and naloxone) sublingual tablet (CIII) is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.

Treatment should be initiated under the direction of physicians who are certified under the Drug Addiction Treatment Act of 2000, and who have been assigned a unique identification number (“X” number).

IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS
• ZUBSOLV sublingual tablet should not be used by patients hypersensitive to buprenorphine or naloxone, as serious adverse reactions, including anaphylactic shock, have been reported

WARNINGS AND PRECAUTIONS
• ZUBSOLV sublingual tablet can be abused in a manner similar to other opioids, legal or illicit. Clinical monitoring appropriate to the patient’s level of stability is essential. Multiple refills should not be prescribed early in treatment or without appropriate patient follow-up visits
• ZUBSOLV sublingual tablet can cause serious, life-threatening, respiratory depression and death, particularly when taken by the intravenous (IV) route in combination with benzodiazepines or other central nervous system (CNS) depressants (eg, sedatives, tranquilizers, or alcohol). Patients should be warned against self-administration or misuse of these combinations
• Dose reduction of CNS depressants, ZUBSOLV sublingual tablet, or both should be considered in situations of concomitant prescription
• Children who take ZUBSOLV sublingual tablet can have severe, possibly fatal, respiratory depression
• Intravenous misuse or taking ZUBSOLV sublingual tablet before the ZUBSOLV sublingual tablet is not appropriate as an analgesic. There can cause serious, life-threatening, respiratory depression and death, particularly when taken by the IV route in combination with benzodiazepines or other central nervous system (CNS) depressants (eg, sedatives, tranquilizers, or alcohol). Patients should be warned against self-administration or misuse of these combinations

ADVERSE REACTIONS
• Adverse events commonly observed with the sublingual administration of buprenorphine/naloxone sublingual tablets during clinical trials and post-marketing experience are headache, nausea, vomiting, hypotension, constipation, and symptoms of withdrawal, insomnia, pain, and peripheral edema
• This is not a complete list of potential adverse events associated with buprenorphine/naloxone sublingual tablets. Please see full Prescribing Information for a complete list
• To report an adverse event associated with taking ZUBSOLV sublingual tablet, please call 1-888-ZUBSOLV (1-888-982-7658). You are encouraged to report adverse events of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

No statistically significant difference in withdrawal symptoms (COWS) from Suboxone film³

Study patient numbers = 758 patients with opioid dependence for a mean of 11 years

To learn more about ZUBSOLV, visit www.zubsolv.com

For IS IT TIME FOR A CHANGE IN TREATMENT FOR YOUR OPIOID DEPENDENT PATIENTS?
Help patients take a different path to recovery

ZUBSOLV demonstrated comparable efficacy compared to patients who received Suboxone film.³

After experiencing both ZUBSOLV and Suboxone film, more than 70% of patients preferred ZUBSOLV attributes such as taste, mouthfeel, and ease of administration.¹

No statistically significant difference in cravings¹

(21.6 with ZUBSOLV vs. 19.1 with Suboxone film, mean VAS score at Day 15)

2. See below for full indication and Important Safety Information